Ad is loading...
MENU

BDRX Stock Biodexa Pharmaceuticals (BDRX, $4.57) Moving Average Convergence Divergence (MACD) Histogram turned positive on November 22, 2024

A.I.dvisor
at Tickeron.com
Loading...
BDRX - Biodexa Pharmaceuticals plc
MACD signal
Bullish Trend
Odds of UP Trend
Tickeron
MACD signal
Price: $4.57
Daily change: +$0.17 (+3.86%)
Daily volume: 223.8K
Capitalization: $2.7M
Industry: Biotechnology
This is a Bullish indicator signaling BDRX's price could rise from here. Traders may explore going long the stock or buying call options. A.I. dvisor identified 50 similar cases where BDRX's MACD histogram became positive, and of them led to successful outcomes. Odds of Success:

BDRX's RSI Oscillator ascending out of oversold territory

The RSI Indicator for BDRX moved out of oversold territory on November 21, 2024. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 46 similar instances when the indicator left oversold territory. In of the 46 cases the stock moved higher. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 19 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

The Moving Average Convergence Divergence (MACD) for BDRX just turned positive on November 22, 2024. Looking at past instances where BDRX's MACD turned positive, the stock continued to rise in of 50 cases over the following month. The odds of a continued upward trend are .

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where BDRX advanced for three days, in of 191 cases, the price rose further within the following month. The odds of a continued upward trend are .

BDRX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 04, 2024. You may want to consider selling the stock, shorting the stock, or exploring put options on BDRX as a result. In of 94 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BDRX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for BDRX entered a downward trend on November 20, 2024. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.242) is normal, around the industry mean (13.849). P/E Ratio (0.000) is within average values for comparable stocks, (88.142). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.810). BDRX has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.012). P/S Ratio (18.797) is also within normal values, averaging (223.470).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. BDRX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BDRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
BDRX
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a company which designs and manufactures nanomedicines

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
1 Caspian Point
Phone
+44 2920480180
Employees
27
Web
https://www.biodexapharma.com